Pharmaceutical giant Bristol Myers Squibb plans to invest $2.3B to build a 600K SF manufacturing campus in Northeast Houston’s Generation Park, the company announced Monday.

The Houston campus, expected to create nearly 500 skilled jobs, will be “modular and multi-modal,” designed with flexibility to grow and reconfigure to meet future pipelines and commercial needs.

BMS’ announcement comes nearly a year after pharmaceutical giant Eli Lilly confirmed it would build a $6.5B synthetic medicine active pharmaceutical product facility in Generation Park, a 4,300-acre master-planned district from McCord Development.

“Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” Greater Houston Partnership CEO Steve Kean said in a statement, adding that the investment will strengthen Houston’s standing as a leading hub for life sciences innovation and investment.

BMS selected Texas and Generation Park following an extensive evaluation of competitive markets in the central and eastern U.S., the company said. BMS said the local life sciences workforce, incentives, proximity to utilities and transportation infrastructure, and a business climate conducive to long-term growth were factors in its selection of Houston. 

“This highly competitive process validates the role our site plays as a vital life science asset both in Texas and nationally,” Generation Park Management District Executive Director Jennifer Mott said. “Our commitment to critical investments in infrastructure and a curated ecosystem continues to attract high-value industry clusters that drive long-term prosperity for the region.”

Eli Lilly chose Generation Park for its facility from a list of more than 300 proposals and applications. McCord officials said infrastructure, speed to market, and educational and workforce partnerships helped them land the investment. 

BMS, a New Jersey-based biopharmaceutical company that researches, develops and creates medicines to treat serious diseases, said this announcement is part of its planned five-year, $40B investment across U.S. research and development, technology and domestic manufacturing. 

The Houston campus’s multimodal design will allow BMS to manufacture several types of medicines, such as small molecules, biologics and antibody-drug conjugates.

“This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation,” Bristol Myers Squibb CEO Christopher Boerner said. “As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”